Lunai Bioworks (NASDAQ: LNAI) Launches National Chemical Defense Consortium Targeting $400M-$1.2B U.S. Countermeasure Programs; 3-Year AI Antidote Development Model Accessibility StatementSkip Navigation AI platform integrates academic and defense research to accelerate rapid antidote discovery and federal stockpiling for emerging chemical threats. SACRAMENTO, Calif., March 19, 2026 /PRNewswire/ -- Lunai Bioworks (NASDAQ: LNAI), through its wholly owned subsidiary BioSymetrics, today announced the formation ...

Financial Data and Key Metrics Changes - In 2025, total revenues increased by 20% to $591 million, while adjusted EBITDA rose by 27% to $137 million, reflecting strong financial performance [9][36] - For Q4 2025, total revenues were up 13% year-on-year at $173 million, with licensing revenues constituting 75% of the total [34][36] - The gross margin for the year was 61%, driven by the mix of licensing revenues [36] Business Line Data and Key Metrics Changes - The company has 30 biosimilars in development, representing over $185 billion in global sales potential [9][27] - Product revenues were $43 million in Q4 2025, with a negative product margin of 37% due to timing of orders and planned facility upgrades [34] - The commercial momentum for biosimilars like AVT02 and AVT04 is expected to continue into 2026, with AVT02 holding a 9% market share in the U.S. [75] Market Data and Key Metrics Changes - In the U.S. market, the originator of Humira held approximately 70% at the beginning of 2025, which declined to around 45% by year-end, indicating a shift towards biosimilars [18] - SIMLANDI has captured about 9% of the U.S. market, making it one of the fastest-growing biosimilars [19] - In Europe, Uzpruvo has established a leading position with over 20% share of the biosimilar segment [19] Company Strategy and Development Direction - The company aims to strengthen its operational platform and expand its manufacturing capabilities, including dual sourcing initiatives [5][15] - Alvotech is focused on advancing its biosimilar portfolio towards approval and commercialization, particularly in the U.S. market [45] - The company anticipates significant opportunities in the biosimilar market due to over 100 biologics expected to lose patent protection in the next decade [7][27] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in addressing regulatory observations from the FDA and expects to resubmit applications in Q2 2026 [4][26] - The company is well-positioned to benefit from recent FDA guidance that reduces the need for large efficacy trials, thus lowering development costs [8][30] - The outlook for 2026 is reaffirmed with expected revenues between $650 million and $700 million, reflecting continued double-digit growth [42] Other Important Information - The company raised close to $300 million from capital markets to support ongoing investments in development and manufacturing [17] - Alvotech's shares were listed on Nasdaq Stockholm, enhancing its presence in the Nordic and European markets [17] Q&A Session Summary Question: U.S. approvals and pending items - Management confirmed completion of remediation efforts and is compiling information to support the upcoming submission, aiming for the end of Q1 or early Q2 2026 [49] Question: Guidance for 2026 - The lower end of the revenue guidance does not include U.S. launch revenues, while the upper end reflects aspirations including potential U.S. launches [50][56] Question: Incremental commercial approvals needed - The guidance is based on momentum from existing approvals, with no new approvals factored in for the lower end of the range [56] Question: Manufacturing platform expansion - The expansion is expected to occur in the first half of 2026, with costs aligned with anticipated R&D expenditures [57] Question: Competitive landscape and risk mitigation - Management emphasized the importance of being first to market and strategic IP positioning to mitigate competitive exposure [68]

Core Viewpoint - Niagen Bioscience, Inc. has announced an increase in its share repurchase program from $10 million to $20 million, reflecting the company's commitment to enhancing shareholder value through strategic capital allocation [1] Company Summary - The Board of Directors of Niagen Bioscience, Inc. has authorized the increase in the share repurchase program, which will now allow for the repurchase of up to $20 million of the company's outstanding common stock [1] - The company has repurchased approximately $10 million worth of its shares through March 17, 2026, indicating a proactive approach to managing its capital structure and returning value to shareholders [1]

- Purchase commitment is for a minimum of $1.475 million of Symvess product -DURHAM, N.C., March 19, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that it has received a minimum purchase commitment of $1.475 million of the Symvess acellular tissue engineered vessel to facilitate a clinical evaluation and outreach program in hospitals within the King ...

Core Viewpoint - Humacyte, Inc. has announced a registered direct offering of 25 million shares of common stock, expected to generate gross proceeds of $20 million to fund the commercialization of its product Symvess and other related activities [1][3]. Group 1: Offering Details - The offering is led by a new life science dedicated investor and a long-only mutual fund [1]. - The expected closing date for the offering is around March 20, 2026, pending customary closing conditions [1]. - Titan Partners, a division of American Capital Partners, is acting as the sole placement agent for the offering [2]. Group 2: Use of Proceeds - The net proceeds will be used to fund the commercialization of Symvess in the vascular trauma indication and the planned filing of a Biologics License Application supplement for hemodialysis [3]. - Additional uses include the development of product candidates in Humacyte's pipeline and general corporate purposes [3]. Group 3: Company Overview - Humacyte is a commercial-stage biotechnology platform company focused on developing universally implantable, bioengineered human tissues at commercial scale [6]. - The company launched Symvess, its first FDA-approved product, in the United States in the first quarter of 2025 [6]. - Humacyte aims to improve patient outcomes and transform medical practices through its regenerative medicine technology [6].

Core Viewpoint - MindBio Therapeutics Corp. is increasing its non-brokered private placement from $650,000 to up to $1,500,000 to support its AI-driven voice analytics technology for drug and alcohol intoxication detection [1] Group 1: Offering Details - The company plans to issue up to 2,500,000 units at a price of $0.60 per unit, aiming for gross proceeds of up to $1,500,000 [1] - Each unit will consist of one common share and one share purchase warrant, with warrants allowing the purchase of additional shares at $0.80 for 36 months [1] - The offering is subject to final board and regulatory approvals, and all securities will have a four-month-and-one-day resale restriction [2] Group 2: Company Overview - MindBio is focused on commercializing AI prediction technologies for detecting drug and alcohol intoxication through voice analysis [3] - The AI model utilizes over 50 million data points to accurately predict alcohol intoxication based solely on voice [3] - The company is developing an enterprise platform that includes Edge-AI kiosks for various industries such as mining, aviation, construction, and law enforcement [3]

Core Viewpoint - Aptevo Therapeutics Inc. is actively participating in key industry conferences to enhance its visibility and engagement with investors and analysts [1] Company Participation - Aptevo Therapeutics will attend the 38th Annual Roth Conference from March 22-24, 2026, in Dana Point, CA [1] - Incoming President and CEO Jeff Lamothe will engage in a fireside chat focused on the company, alongside analyst Jonathan Aschoff [1]

Core Insights - The article highlights the significance of aligning inflammatory biomarker enrichment with the mechanism of action in Alzheimer's drug development, specifically focusing on INmune Bio's Phase 2 MINDFuL trial of XPro™ [1][2] Group 1: Research and Development - Dr. Malú Gámez Tansey will present the MINDFuL trial results at the AD/PD 2026 conference, emphasizing the role of peripheral inflammation in neurodegenerative diseases [1][2] - The MINDFuL trial enrolled Alzheimer's patients with measurable peripheral inflammation, demonstrating that nearly all efficacy endpoints favored XPro1595 in this subgroup, indicating successful patient identification [3][4] - INmune Bio is advancing to a Phase 2b/3 registrational program for XPro1595, following positive feedback from the FDA, focusing on early Alzheimer's patients enriched for inflammatory biomarkers [5][6] Group 2: Mechanism of Action - XPro™ is a next-generation inhibitor of tumor necrosis factor (TNF) that selectively neutralizes soluble TNF, potentially reducing neuroinflammation and improving cognitive function in patients with neurological diseases [7] - The biomarker enrichment strategy in MINDFuL is compared to precision approaches that have transformed cancer treatment, suggesting a promising direction for Alzheimer's therapy [4] Group 3: Company Overview - INmune Bio Inc. is a clinical-stage biotechnology company focused on developing treatments targeting the innate immune system, with three product platforms: CORDStrom™, XPro™, and INKmune® [8]

Core Insights - Annovis Bio, Inc. has announced a partnership with NeuroRPM to implement an FDA-cleared AI platform for monitoring Parkinson's disease symptoms in its ongoing clinical study of the investigational therapy, buntanetap [1][2]. Company Overview - Annovis Bio, Inc. is a Phase 3 clinical-stage biotechnology company focused on developing treatments for neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease [9]. - The lead drug candidate, buntanetap, is an investigational oral therapy aimed at inhibiting neurotoxic proteins to halt disease progression and improve cognitive and motor functions [9]. Partnership Details - The partnership with NeuroRPM aims to enhance data collection and monitoring in the open-label study (ANVS-25002) currently enrolling participants across 25 sites in the U.S. [2][6]. - NeuroRPM's AI-enabled medical device will monitor primary Parkinson's symptoms such as bradykinesia, tremor, and dyskinesia, providing real-time digital biomarkers [2][4]. Study Progress - The ANVS-25002 study has enrolled 90 out of an estimated total of 500 patients, with the study duration set for 36 months [6]. - Participants may have the option to continue using NeuroRPM technology for clinical monitoring after the study [6]. Technological Innovations - NeuroRPM's platform allows for continuous wearable monitoring, providing objective measurements of treatment response in real-world settings [5][7]. - The study will also utilize a highly accurate biomarker test for misfolded phosphorylated alpha-synuclein, which has over 90% diagnostic sensitivity and specificity [5]. Benefits of Digital Biomarkers - The collaboration is expected to yield data-driven insights that will enhance the understanding of disease progression and inform future clinical trial designs [3][5]. - The combination of digital and biological biomarkers aims to comprehensively record patient responses to treatment, improving the precision of outcome measurements [5].

Core Viewpoint - Vesicor Therapeutics, Inc. has appointed Dr. Michael Tolentino as the new CEO, succeeding founder Dr. Luo Feng, as the company aims to advance its p53-based cancer therapeutics and complete a proposed de-SPAC merger with Black Hawk Acquisition Corporation [1][2]. Company Overview - Vesicor Therapeutics is an early development stage biotechnology company based in San Gabriel, California, focusing on p53-based cancer therapeutics delivered via precision-engineered microvesicles [1]. - The company is in the process of a proposed merger with Black Hawk Acquisition Corporation, a SPAC, to accelerate its development efforts [2]. Leadership Appointment - Dr. Michael Tolentino brings over 20 years of experience in the biotechnology sector and has a proven track record in drug discovery and development [3]. - His previous roles include significant contributions to the development of Avastin and Bevasiranib, showcasing his expertise in both pre-clinical and clinical development [3][4]. Strategic Goals - Dr. Tolentino expressed his commitment to building upon Vesicor's technology and aims for an Investigational New Drug (IND) submission to the FDA by 2027 [2]. - The company is focused on developing potent cancer therapeutics and creating shareholder value through its innovative approaches [2]. Financial and Development Background - Dr. Tolentino has a history of successful ventures, including the sale of Promedior, Inc. to Roche for $390 million, with potential contingent payments up to $1 billion [4]. - He has co-founded multiple biotechnology companies, including Aviceda Therapeutics, which secured $207.5 million in Series C financing [6]. Research and Development Focus - Vesicor's therapeutic approach involves using microvesicles to deliver cancer-targeting agents, including p53 gene delivery and other chemotherapeutics [9]. - The company aims to leverage advanced technologies and collaborations to enhance its drug development pipeline [8].